Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CVTX - CV Therapeutics, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (291)	12/4/2006 4:08:00 PM
From: mopgcw	Read Replies (1) \| Respond to of 411

a good tidbit, but it hinges on angina...i am still in, basis of 12, meant to reload when it 10, but missed it through lack of focus. am comfortable owning it at these levels, not sure if i would add more unless it dips in to 10 range again. fwiw. george

To: tuck who wrote (291)	3/6/2007 5:12:01 PM
From: dr.praveen	Respond to of 411

CV Therapeutics Announces Topline MERLIN TIMI-36 Results Tuesday March 6, 4:01 pm ET - Full study results will be presented at the American College of Cardiology's Scientific Session - PALO ALTO, Calif., March 6 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX - News) announced today that an analysis of unblinded data from the MERLIN TIMI-36 study of ranolazine shows there was no adverse trend in death or arrhythmias in patients on ranolazine. The study did not meet the primary efficacy endpoint. In accordance with the company's special protocol assessment agreement with the U.S. Food and Drug Administration (FDA), the company believes that the data could support expansion of the existing Ranexa® (ranolazine extended-release tablets) indication to include first line angina. Complete data are scheduled to be presented as a late breaking clinical trial on Tuesday, March 27 at 8:50 a.m. central time during the 2007 American College of Cardiology Scientific Session in New Orleans. Study Design MERLIN TIMI-36 (Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes) is a multi-national, double-blind, randomized, placebo-controlled, parallel-group clinical trial designed to evaluate the efficacy and safety of Ranexa during acute and long-term treatment in approximately 6,500 patients with non-ST elevation ACS treated with standard therapy. Within 48 hours of the onset of angina due to ACS, eligible hospitalized patients were enrolled in the study and randomized to receive intravenous Ranexa or placebo, followed by long-term outpatient treatment with Ranexa extended-release tablets or placebo. All patients also received standard therapy during both hospital-based and outpatient treatment. The doses of Ranexa extended-release tablets used in MERLIN TIMI-36 have been studied in previous Phase 3 clinical trials. Currently, Ranexa is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates. <Discl: I don't have any position. Stock off 25% AH>